Skip to main content
Premium Trial:

Request an Annual Quote

PrognosDx, MMRI Ink Epigenetics R&D Collaboration

NEW YORK (GenomeWeb News) – PrognosDx Health and the Molecular Medicine Research Institute announced recently a broad collaborative R&D agreement aimed at using PrognosDx's technology for the development of a new class of epigenetic therapeutics.

The deal provides Palo Alto, Calif.-based PrognosDx with resources to launch CLIA lab services, including a prostate cancer prognosis test and predictive tests for other cancers, the partners said.

PrognosDx now also will have a "platform for introductions to select pharma partners" for the development of new epigenetic therapeutics based on its recent "breakthrough discoveries." Initially, it and MMRI will focus on treatments for hormone refractory prostate cancer using PrognosDx's genome-wide histone modification-based biomarkers and cellular metabolism-related therapeutic insights to analyze clinical samples and carry out preclinical studies. They also plan to collaborate with academic centers on breast and gastrointestinal cancers.

As a result of the collaboration, Edward Amento, founder and executive director of MMRI, has joined PrognosDx's board.

PrognosDx uses epigenetic technology for the analysis of global histone modifications, allowing physicians to tailor cancer treatments for individual patients. Sunnyvale, Calif.-based MMRI is a non-profit institute which offers preclinical and clinical services. Its 31,000-square-foot lab has molecular biology, immunohistochemistry, flow cytometry, medicinal chemistry, cell culture, preclinical models, and other technical resources.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.